Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

Lannett cannot possibly sustain their Levo supply agreement at current terms. This distribution deal, which expires in 2019, will either fall due to price fixing, or be dramatically repriced.

Lannett finds itself at a confluence of choices brought forth more by management than the macro-environment. Click here to learn more about LCI stock.

Lannett CEO Arthur Bedrosian has slammed Shkreli. Yet his company boosted the cost of fluphenazine, which treats certain kinds of schizophrenia, to a net price of $195.53 from $11.17 between April ...

Shares in Lannett Co. plunged 55% Monday after the generic-pharmaceuticals maker said a distribution pact with a key supplier won’t be renewed next year and that it would expand restructuring ...

Lannett is selling its liquid drug manufacturing facility in Carmel, N.Y., as well as equipment located at the facility, certain ANDAs and other assets to a private company for $10.5 million in ...

Shares of Lannett were up 12% at $55.41 on Thursday afternoon. The stock has a consensus analyst price target of $64.60 and a 52-week trading range of $37.19 to $72.44.

Lannett’s stock dropped 26.6% on Thursday, more than any other company that has told investors about the price collusion probe, including Endo International, Mylan and Teva Pharmaceuticals.